# A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

> **NCT06630871** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 40 (estimated)

## Conditions studied

- NMIBC

## Interventions

- **DRUG:** Distitamab Vedotin in combination with Tislelizumab

## Key facts

- **NCT ID:** NCT06630871
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-10
- **Final completion:** 2028-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-10-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630871, "A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06630871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*